Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 15, 2024 (filed on Apr 16, 2024)Insider Name:Damico Jennifer B.Ownership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:54Price:$25.91
-
Apr 15, 2024 (filed on Apr 16, 2024)Insider Name:Bourla AlbertOwnership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20Price:$25.91
-
Apr 10, 2024 (filed on Apr 11, 2024)Insider Name:Damico Jennifer B.Ownership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:108Price:$26.32
-
Apr 10, 2024 (filed on Apr 11, 2024)Insider Name:Bourla AlbertOwnership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18Price:$26.32
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Damico Jennifer B.Ownership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:49Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Bourla AlbertOwnership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Smith James COwnership Type:Direct OwnershipSecurities:Phantom Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,622Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Quincey JamesOwnership Type:Direct OwnershipSecurities:Phantom Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,396Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Narayen ShantanuOwnership Type:Direct OwnershipSecurities:Phantom Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,802Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Echevarria JosephOwnership Type:Direct OwnershipSecurities:Phantom Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,667Price:$27.75
Filings by filing date
-
Apr 15, 2024 (filed on Apr 16, 2024)Insider Name:Damico Jennifer B.Ownership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:54Price:$25.91
-
Apr 15, 2024 (filed on Apr 16, 2024)Insider Name:Bourla AlbertOwnership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:20Price:$25.91
-
Apr 10, 2024 (filed on Apr 11, 2024)Insider Name:Damico Jennifer B.Ownership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:108Price:$26.32
-
Apr 10, 2024 (filed on Apr 11, 2024)Insider Name:Bourla AlbertOwnership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:18Price:$26.32
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Damico Jennifer B.Ownership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:49Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Bourla AlbertOwnership Type:Direct OwnershipSecurities:Phantom Stock Units SSPNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Smith James COwnership Type:Direct OwnershipSecurities:Phantom Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,622Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Quincey JamesOwnership Type:Direct OwnershipSecurities:Phantom Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,396Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Narayen ShantanuOwnership Type:Direct OwnershipSecurities:Phantom Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,802Price:$27.75
-
Mar 28, 2024 (filed on Apr 01, 2024)Insider Name:Echevarria JosephOwnership Type:Direct OwnershipSecurities:Phantom Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:1,667Price:$27.75
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 66 HUDSON BOULEVARD EAST NEW YORK NY 10001-2192 |
Tel: | N/A |
Website: | https://www.pfizer.com |
IR: | See website |
Key People | ||
Albert Bourla Chairman of the Board, Chief Executive Officer | Michael Mcdermott Executive Vice President, Chief Global Supply Officer | David M. Denton Executive Vice President, Chief Financial Officer |
Payal Sahni Executive Vice President, Chief People Experience Officer | Lidia L. Fonseca Executive Vice President, Chief Digital and Technology Officer | Rady A. Johnson Executive Vice President, Chief Compliance, Quality and Risk Officer |
Douglas M. Lankler Executive Vice President, General Counsel | Chris Boshoff Executive Vice President, Chief Oncology Officer | Alexandre De Germay Executive Vice President, Chief International Commercial Officer | Aamir Malik Executive Vice President, Chief US Commercial Officer |
Business Overview |
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its Oncology products include Ibrance, Xtandi, Inlyta, Bosulif, Lorbrena, Braftovi, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio and Tivdak. Its primary care products include Eliquis, Nurtec ODT/Vydura, Comirnaty, the Prevnar family, Abrysvo, FSME/IMMUN-TicoVac, Paxlovid and Lucira by Pfizer. Its specialty care products include Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra, Cibinqo, Litfulo, Vyndaqel family, Genotropin, Sulperazon, Zavicefta, Medrol and Panzyga. |
Financial Overview |
For the fiscal year ended 31 December 2023, Pfizer Inc revenues decreased 42% to $58.5B. Net income before extraordinary items decreased 93% to $2.13B. Revenues reflect United States segment decrease of 36% to $27.09B, Developed Europe segment decrease of 47% to $11.65B. Net income also reflects Certain asset impairments increase from $421M to $3.02B (expense), Amortization of intangible assets increase of 31% to $4.73B (expense). |
Employees: | 88,000 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $207,953M as of Dec 31, 2023 |
Annual revenue (TTM): | $58,497M as of Dec 31, 2023 |
EBITDA (TTM): | $19,183M as of Dec 31, 2023 |
Net annual income (TTM): | $2,134M as of Dec 31, 2023 |
Free cash flow (TTM): | -$4,454M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $59,198M as of Dec 31, 2023 |
Shares outstanding: | 5,662,541,291 as of Feb 28, 2024 |
Index Membership: | S&P 500 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |